Actelion
 Actelion logo | |
 | |
| public company | |
| Industry | Pharmaceuticals/Biotech |
| Founded | 1997 |
| Founder | Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann |
| Headquarters | Gewerbestrasse 16, Allschwil, Basel country, Switzerland |
Area served | Research and Development of medicines for unmet medical need |
Key people |
Jean-Paul Clozel, Chief Executive Office Guy Braunstein, Global Clinical Development Otto Schwarz, Chief Operating Officer Nicholas Franco, Chief Business Officer André C. Muller, Chief Financial Officer; (Robert Cawthorn, President of the Board [will step back in 2012]) |
| Products | Tracleer, Ventavis, Zavesca, Veletri, Opsumit |
| Revenue | 1,929 mio CHF (Annual Report [1]) |
| 457.3 mio CHF | |
| 390.6 mio CHF | |
Number of employees | 2467 (January 2011) |
| Website |
www |
Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel in Switzerland.[2]
Actelion specializes in orphan diseases.[3] Actelion scientists were among the first to work in the field of endothelian receptor antagonists.[4] The company name might be a reminder for its first product, an endothelian receptor antagonist and the verb "action", "act upon". Actelion was initially financed with venture capital provided through a syndicate including Atlas Venture, Sofinnova and HealthCap.
Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. The Swiss affiliate is located in Baden, the German affiliate in Freiburg, the Austrian one in Vienna, the French one in Paris and the UK affiliate is located in London[5]
In 2006, the company established the Actelion Endothelin Research Award programme which supports selected clinical research projects.
In January 2017, Johnson & Johnson announced that it would purchase the company for $30 billion.[6] Actelion's research and development unit would also be spun off after the acquisition.[7] The new company Idorsia was created from former Actelion drug discovery operations and early-stage clinical development assets and listed in June 2017 on the SIX Swiss Exchange.[8]
In 2018, Johnson & Johnson announced they would discontinue development of one of the phase III drugs it acquired during its purchase of Actelion.[2]
Medicines
Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for orphan diseases:
- Tracleer (bosentan): Tracleer was the first oral treatment approved for pulmonary arterial hypertension, a rare, chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. It is a dual endothelin receptor antagonist, see also: Endothelin receptor antagonist.[9]
- Zavesca (miglustat): is currently the only approved oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Type 1 Gaucher disease is a rare and debilitating metabolic disorder.[10]
- Ventavis (iloprost): Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms.[11]
- Veletri (epoprostenol for injection): is approved by the U.S. Food and Drug Administration (FDA) for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.[12]
Pipeline
Late-stage drugs in development by Actelion include:
- Cadazolid for c. diff-associated diarrhea
- Macitentan for pediatric PAH and portopulmonary hypertension
- Ponesimod for multiple sclerosis[13]
Key figures
By January 2011, Actelion had a total of 2,467 employees, 392 in research, 640 in development and 1017 in sales and marketing. In 2010, Actelion's sales amounted to 1,929 million CHF.[14]
Actelion's shares have been listed on the SIX Swiss Exchange (ticker symbol ATLN) since 2000 SWX Swiss Exchange Swiss Leader Index. In September 2008, Actelion shares began trading as part of the Swiss Market Index.[15][16][17]
Awards
Actelion received the "Prix Hermès de l'innovation" (Hermès Award for Innovation) in April 2011:[18] The "European Institute for Creative Strategy and Innovation", the creator of the Prix Hermès, was founded in 2003 in France.
The "performance report for Swiss pharma websites" awarded Actelion the first Prize in the second consecutive year:.[19]
Notes and references
- ↑ https://web.archive.org/web/20110303032258/http://www1.actelion.com/en/our-company/news-and-events/index.page?newsId=1489892. Archived from the original on 3 March 2011. Missing or empty
|title=(help) - 1 2 Taylor, Nick Paul (17 April 2018). "Johnson & Johnson scraps phase 3 antibiotic program acquired in $30B Actelion takeover". Fierce Biotech. Retrieved 5 July 2018.
- ↑ "Medicine".
- ↑ "Businessweek".
- ↑ "Actelion affiliates".
- ↑ Roland, Denise; D. Rockoff, Jonathan (January 26, 2017), Johnson & Johnson to Acquire Actelion in $30 Billion Deal, Wall Street Journal, retrieved January 27, 2017
- ↑ "Johnson & Johnson to buy Actelion for $30 billion, spin off R&D unit". Reuters. 26 January 2017. Retrieved 26 January 2017.
- ↑ Clozel, Jean-Paul. "About Idorsia history". www.idorsia.com. Retrieved 19 August 2018.
- ↑ "European Medicines Agency".
- ↑ "European Medicines Agency".
- ↑ "European Medicines Agency".
- ↑ "News Medical".
- ↑ https://www1.actelion.com/en/scientists/development-pipeline/index.page?
- ↑ "Actelion company homepage". Archived from the original on 22 February 2011. Retrieved 7 March 2011.
- ↑ "Swiss Market Index".
- ↑ "UBS".
- ↑ "The Pharmaletter".
- ↑ "Prix Hermès". Archived from the original on 2010-12-21.
- ↑ "Prize for Website" (PDF). Archived from the original (PDF) on 23 March 2012.
See also
External links
 |
Wikimedia Commons has media related to Actelion. |
